US 12,433,918 B2
Methods of treating joint disease, disorders, and conditions with tissue inhibitors of matrix metalloproteinase
Jeffrey S. White, Birchrunville, PA (US); and Robin R. Young, Beaverton, OR (US)
Assigned to Prime Merger Sub, LLC, Birmingham, AL (US)
Filed by Prime Merger Sub, LLC, Birmingham, AL (US)
Filed on Apr. 28, 2023, as Appl. No. 18/141,056.
Application 18/141,056 is a continuation of application No. 16/746,541, filed on Jan. 17, 2020, granted, now 11,666,606.
Application 16/746,541 is a continuation of application No. 15/086,985, filed on Mar. 31, 2016, granted, now 10,576,107, issued on Mar. 30, 2020.
Claims priority of provisional application 62/140,909, filed on Mar. 31, 2015.
Prior Publication US 2024/0058391 A1, Feb. 22, 2024
Int. Cl. A61K 35/50 (2015.01); A61K 38/57 (2006.01); A61L 27/36 (2006.01); A61L 27/54 (2006.01); A61K 9/00 (2006.01); A61K 47/36 (2006.01)
CPC A61K 35/50 (2013.01) [A61K 38/57 (2013.01); A61L 27/3604 (2013.01); A61L 27/54 (2013.01); A61K 9/0019 (2013.01); A61K 47/36 (2013.01); A61L 2300/434 (2013.01); A61L 2430/24 (2013.01)] 20 Claims
 
1. A method of treating a joint disease, disorder, or condition in a subject in need thereof, the method comprising injecting a composition comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) into a joint of the subject, thereby treating the joint disease, disorder, or condition, wherein the joint disease, disorder, or condition is associated with degradation of cartilage by proteases and the composition includes an amniotic fluid from which the TIMPS originate that is obtained from a pregnant female donor during a Caesarean section procedure, the amniotic fluid including a concentration of urea of no more than 160 mg/L, a concentration of uric acid of no more than 80 g/L and a concentration of creatinine of no more than 14 mg/L.